Nikko Asset Management Americas Inc. Sells 250,244 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Nikko Asset Management Americas Inc. lowered its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 10.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,065,050 shares of the biotechnology company's stock after selling 250,244 shares during the period. Nikko Asset Management Americas Inc. owned approximately 7.62% of Arcturus Therapeutics worth $34,941,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Los Angeles Capital Management LLC acquired a new stake in Arcturus Therapeutics in the 3rd quarter worth approximately $544,000. Royce & Associates LP raised its position in shares of Arcturus Therapeutics by 18.3% in the third quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company's stock valued at $3,616,000 after purchasing an additional 24,085 shares during the period. Quest Partners LLC raised its position in shares of Arcturus Therapeutics by 437.1% in the third quarter. Quest Partners LLC now owns 19,810 shares of the biotechnology company's stock valued at $460,000 after purchasing an additional 16,122 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Arcturus Therapeutics by 28.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 48,957 shares of the biotechnology company's stock worth $1,136,000 after buying an additional 10,728 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company's stock worth $4,587,000 after buying an additional 3,224 shares during the period. Institutional investors own 94.54% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research analysts recently commented on ARCT shares. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Canaccord Genuity Group decreased their target price on Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research note on Monday, March 10th. HC Wainwright dropped their price target on Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Finally, Wells Fargo & Company reduced their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $59.20.

Arcturus Therapeutics Stock Up 0.3 %

Arcturus Therapeutics stock traded up $0.04 on Friday, hitting $12.88. The company's stock had a trading volume of 559,253 shares, compared to its average volume of 455,113. The company has a fifty day moving average price of $16.17 and a 200-day moving average price of $18.12. Arcturus Therapeutics Holdings Inc. has a one year low of $12.11 and a one year high of $45.00. The firm has a market cap of $349.31 million, a P/E ratio of -5.80 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million. Analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.